Patents by Inventor Wilhelm Krek

Wilhelm Krek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220162711
    Abstract: A cell-based screening method is provided. The screening method aims to identify drugs for the treatment of cancers characterized by cells with an over-activated signalling pathway in a combination medicament with an inhibitor of the respective over-activated signalling pathway. In particular, the expression level of SOX2 is determined to identify compounds that prevent the development of resistance to inhibitors of the MAPK and EGFR pathway.
    Type: Application
    Filed: February 7, 2022
    Publication date: May 26, 2022
    Inventors: Wilhelm KREK, Stefanie FLUCKIGER-MANGUAL
  • Publication number: 20210179591
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is selected from fluoro, methoxy and ethoxy, each R2 is independently selected from hydrogen, fluorine and methyl, n is O, 1, 2, 3, 4 or 5, R3 is selected from hydrogen, fluorine, amino, hydroxy, and a five or six membered substituted or unsubstituted ring system which may be aromatic or aliphatic, comprising 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen, R4 is hydrogen or methyl, for use as a therapeutically active substance.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 17, 2021
    Inventors: Blaise CALPE, Wilhelm KREK, Gisbert SCHNEIDER, Petra SCHNEIDER
  • Publication number: 20200325543
    Abstract: The present invention is in the field of cancer diagnosis. In particular, the present invention relates to a method for determining in a cancer patient the risk of develop a resistance to chemical substances used in cancer therapy. The invention furthermore provides a novel combination therapy for patients that have been diagnosed to develop drug resistance against chemical substances used for treating cancer.
    Type: Application
    Filed: November 20, 2018
    Publication date: October 15, 2020
    Inventors: Stefanie FLÜCKIGER-MANGUAL, Wilhelm KREK
  • Publication number: 20200087732
    Abstract: A cell-based screening method is provided. The screening method aims to identify drugs for the treatment of cancers characterized by cells with an over-activated signalling pathway in a combination medicament with an inhibitor of the respective over-activated signalling pathway. In particular, the expression level of SOX2 is determined to identify compounds that prevent the development of resistance to inhibitors of the MAPK and EGFR pathway.
    Type: Application
    Filed: December 20, 2017
    Publication date: March 19, 2020
    Applicant: ETH ZURICH
    Inventors: Wilhelm KREK, Stefanie FLUCKIGER-MANGUAL
  • Patent number: 10151755
    Abstract: The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 11, 2018
    Assignees: ETH ZURICH, Kantonsspital St. Gallen
    Inventors: Wilhelm Krek, Igor Cima, Rudolf Aebersold, Ralph Schiess, Thomas Cerny, Silke Gillessen
  • Publication number: 20160274117
    Abstract: The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 22, 2016
    Applicants: ETH ZURICH, Kantonsspital St. Gallen
    Inventors: Wilhelm KREK, Igor CIMA, Rudolf AEBERSOLD, Ralph SCHIESS, Thomas CERNY, Silke GILLESSEN
  • Patent number: 9377463
    Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behavior between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from health
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: June 28, 2016
    Assignees: ETH ZURICH, Kantonsspital St. Gallen
    Inventors: Wilhelm Krek, Igor Cima, Rudolf Aebersold, Ralph Schiess, Thomas Cerny, Silke Gillessen
  • Publication number: 20140322732
    Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healt
    Type: Application
    Filed: June 23, 2014
    Publication date: October 30, 2014
    Applicants: Kantonsspital St. Gallen, ETH ZURICH
    Inventors: Wilhelm KREK, Igor CIMA, Rudolf AEBERSOLD, Ralph SCHIESS, Thomas CERNY, Silke GILLESSEN
  • Publication number: 20110065605
    Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healt
    Type: Application
    Filed: May 12, 2009
    Publication date: March 17, 2011
    Applicants: ETH ZURICH, KANTONSSPITAL ST. GALLEN
    Inventors: Wilhelm Krek, Igor Cima, Rudolf Aebersold, Ralph Schiess, Thomas Cerny, Silke Gillessen
  • Publication number: 20060257367
    Abstract: A polynucleotide comprising an Skp 2 promoter sequence is provided. The promoter is useful in tumour and cancer therapy, in particular in therapies that are intended to selectively kill or reduce the growth, division or viability of tumour or cancer cells compared to surrounding, non-tumour or non-cancer cells. Also provided are methods for screening for inhibitors of Skp2 promoter activity.
    Type: Application
    Filed: February 10, 2006
    Publication date: November 16, 2006
    Inventors: Anne-Isabelle Gallani, Georges Imbert, Wilhelm Krek
  • Publication number: 20040028684
    Abstract: A novel RMP homologue is provided, as well as nucleic acids encoding the protein and antisense nucleic acids, Methods of diagnosing conditions dependent on RMP are provided as well as screening methods for identify agents active against conditions dependent on RMP, such as conditions dependent on amino acid regulation, cancer, neurodegeneration, muscle degeneration, immune disorders, and AIDS.
    Type: Application
    Filed: November 12, 2002
    Publication date: February 12, 2004
    Inventors: Matthias Georg Christian Gstaiger, Wilhelm Krek
  • Publication number: 20030109481
    Abstract: A polynucleotide comprising an Skp 2 promoter sequence is provided. The promoter is useful in tumour and cancer therapy, in particular in therapies that are intended to selectively kill or reduce the growth, division or viability of tumour or cancer cells compared to surrounding, non-tumour or non-cancer cells. Also provided are methods for screening for inhibitors of Skp2 promoter activity.
    Type: Application
    Filed: December 19, 2002
    Publication date: June 12, 2003
    Inventors: Anne-Isabelle Gallani, Georges Imbert, Wilhelm Krek
  • Publication number: 20030104500
    Abstract: Methods of identifying anti-cancer agents are provided based on ligand binding or enzymatic activity of TIP49 family members. The assays may include the measurement of ATPase and/or helicase activity. Also provided are anti-cancer agents identified by the screening methods of the invention, as well as the use of the agent for the prophylaxis or treatment of cancer. A complex of a TIP49 family member with various proteins that regulate transcription is also provided.
    Type: Application
    Filed: November 12, 2002
    Publication date: June 5, 2003
    Inventors: Matthias Georg Christian Gstaiger, Wilhelm Krek
  • Publication number: 20030092054
    Abstract: Protein complexes containing a SKP2 binding protein (STAP1) are provided useful in identifying anti-cancer agents. Also provided are agents identified using the methods for use as therapeutics.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 15, 2003
    Inventors: Matthias Georg Christian Gstaiger, Wilhelm Krek